Trial · NCT00509041
Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma
NCT00509041, Phase 2, Completed, Alliance for Clinical Trials in Oncology; results first posted 2013-01-17
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma. Trials, record NCT00509041. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00509041
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma
- NCT number
- NCT00509041
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 46 participants, actual
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Conditions
- Malignant Mesothelioma
- Interventions
- dasatinib
- First posted
- 2007-07-31
- Last updated
- 2016-08-11
- Results first posted
- 2013-01-17
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 24 Week Progression Free Survival | 24 weeks | Percentage of participants who were alive and progression free at 24 weeks. The 24 week progression free survival, with 95% confidence interval, was estimated using the Kaplan Meier method. |
| Secondary | Number of Participants With Overall Tumor Response | Duration of study until progression (up to 3 years) | Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria: * Complete Response (CR): disappearance of all target lesions; * Partial Response (PR) 30% decrease in sum of longest diameter of target lesions; * Progressive Disease (PD): 20% increase in sum of longest diameter of target lesions; * Stable Disease (SD): small changes that do not meet above criteria. Overall tumor response is the total number of CR and PRs. |
| Secondary | Overall Survival | Time from registration to death (up to 3 years) | Overall survival (OS) was defined as the time from registration to death of any cause. Surviving patients were censored at the date of last follow-up. The median OS with 95% CI was estimated using the Kaplan Meier method. |
| Secondary | Progression Free Survival | Time from registration to progression or death (up to 3 years) | Progression free survival (PFS) was defined as the time from registration to progression or death of any cause. Progression free and alive patients were censored at the date of last follow-up. The median PFS with 95% CI was estimated using the Kaplan Meier method. |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | 24 Week Progression Free Survival | 24 weeks | percentage of participants | NUMBER | |
| SECONDARY | Number of Participants With Overall Tumor Response | Duration of study until progression (up to 3 years) | participants | NUMBER | |
| SECONDARY | Overall Survival | Time from registration to death (up to 3 years) | weeks | MEDIAN | |
| SECONDARY | Progression Free Survival | Time from registration to progression or death (up to 3 years) | weeks | MEDIAN |
Source ClinicalTrials.gov
Results by group5
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| 24 Week Progression Free Survival | Dasatinib | 23 | 95% Confidence Interval 13.5 to 40 | percentage of participants | |
| Number of Participants With Overall Tumor Response | Dasatinib | Complete Response | 0 | participants | |
| Number of Participants With Overall Tumor Response | Dasatinib | Partial Response | 2 | participants | |
| Overall Survival | Dasatinib | 26.1 | 95% Confidence Interval 18.6 to 36.7 | weeks | |
| Progression Free Survival | Dasatinib | 9.1 | 95% Confidence Interval 7.4 to 16.9 | weeks |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Dasatinib | 43 | |
| Overall Study | COMPLETED | Dasatinib | 43 | |
| Overall Study | NOT COMPLETED | Dasatinib | 0 |
Source ClinicalTrials.gov
Adverse events158
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Hemoglobin decreased | Blood and lymphatic system disorders | Dasatinib | 24 | 43 | 64 |
| other | Pericardial effusion | Cardiac disorders | Dasatinib | 1 | 43 | 1 |
| other | Pericarditis | Cardiac disorders | Dasatinib | 1 | 43 | 1 |
| other | Ventricular tachycardia | Cardiac disorders | Dasatinib | 1 | 43 | 1 |
| other | Abdominal distension | Gastrointestinal disorders | Dasatinib | 1 | 43 | 1 |
| other | Abdominal pain | Gastrointestinal disorders | Dasatinib | 4 | 43 | 4 |
| other | Ascites | Gastrointestinal disorders | Dasatinib | 1 | 43 | 1 |
| other | Constipation | Gastrointestinal disorders | Dasatinib | 4 | 43 | 5 |
| other | Diarrhea | Gastrointestinal disorders | Dasatinib | 14 | 43 | 19 |
| other | Dyspepsia | Gastrointestinal disorders | Dasatinib | 3 | 43 | 3 |
1 to 10 of 158Source ClinicalTrials.gov
See all 158 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Dasatinib | ||
| Total, other adverse events | Dasatinib | 35 | 43 |
| Total, serious adverse events | Dasatinib | 15 | 43 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| U10CA031946 | Cancer and Leukemia Group B | BERTAGNOLLI, MONICA M | BRIGHAM AND WOMEN'S HOSPITAL | NATIONAL CANCER INSTITUTE | 1985 to 2013 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00509041
GET https://conductscience.org/api/trials/v1/NCT00509041/events?page=2